FEIBA VH is a therapy for people who have hemophilia A or hemophilia B with inhibitors.
With proven efficacy and safety in different settings, demonstrated over decades of use, only FEIBA can lay claim to a 30 year history of success in the treatment of patients with inhibitors.1,2 FEIBA VH is an anti-inhibitor coagulant complex with factor VIII inhibitor bypassing activity that is indicated for control of spontaneous bleeding episodes or to cover surgical interventions in hemophilia A and hemophilia B patients with inhibitors. In addition, the use of FEIBA IMMUNO (AICC) has been described in a few non-hemophiliacs with acquired inhibitors to factors VIII, XI, and XII.
For more information about FEIBA VH please visit www.hemophiliagalaxy.com.
About The faces of FEIBA VH
Here's your chance to tell your story with The faces of FEIBA VH. Through a new contest sponsored by Baxter, you can submit a written story or video about your experiences with FEIBA VH and share them with other members of the hemophilia community. You could win a $500 scholarship, summer camp grant, or chapter donation, and see your story published online!
Learn more about The faces of FEIBA VH
About Inhibitors
Managing hemophilia is not easy. And having an inhibitor makes it even more of a challenge. This is because an inhibitor prevents the factor you would normally infuse from working, so a stable blood clot cannot form.
Inhibitors, also called antibodies, are a part of your body's natural defense against foreign proteins. If you have an inhibitor, the antibodies try to get rid of the factor VIII or IX you have infused, as though it were an invader.3
Fortunately, hemophilia with inhibitors can be managed with a therapy called FEIBA VH.4
For more information about inhibitors, visit www.hemophiliagalaxy.com.
References: 1. Turecek PL, Varadi K, Gritch H, Schwarz HP. FEIBA®: mode of action. Haemophilia. 2004;10(Suppl 2):3-9. 2. Hilgartner MW, Knatterud GL, and The FEIBA Study Group. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood. 1983;61:36-40. 3. Oldenburg J. Neutralizing Antibodies to FVIII: Risk Factors for Inhibitor Development. Westlake Village, Calif: Baxter Bioscience; 2004. Scientific Series No. 2. 4. FEIBA VH Prescribing Information. Westlake Village, Calif: Baxter Healthcare Corporation; April 2005.
INDICATIONS
FEIBA VH [Anti-Inhibitor Coagulant Complex] is an anti-inhibitor coagulant complex with factor VIII inhibitor bypassing activity that is indicated for control of spontaneous bleeding episodes or to cover surgical interventions in hemophilia A and hemophilia B patients with inhibitors. In addition, the use of FEIBA IMMUNO (AICC) has been described in a few non-hemophiliacs with acquired inhibitors to factors VIII, XI, and XII.
IMPORTANT SAFETY INFORMATION
The use of FEIBA VH is contraindicated in patients who are known to have a normal coagulation mechanism. FEIBA VH should not be given to patients with significant signs of disseminated intravascular coagulation (DIC) or fibrinolysis. In rare instances, thromboembolic events may occur, particularly following the administration of high doses and/or repeated administration and in patients with thrombotic risk factors. Infusion of FEIBA VH should not exceed single dosage of 100 units per kg of body weight and daily doses of 200 units per kg of body weight. Anamnestic responses with a rise in factor VIII inhibitor titer have been observed.
As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. This risk has been reduced by effective donor screening, testing for the presence of certain viral infections, by inactivating and/or removing certain viruses. Also, allergic reactions associated with FEIBA VH have been reported. Symptoms may range from mild, short-term urticarial rashes (hives) to severe anaphylactoid reactions.
View the FEIBA VH Full Prescribing Information [PDF].
